Cargando…
In vitro and in vivo activities of DW-3-15, a commercial praziquantel derivative, against Schistosoma japonicum
BACKGROUND: Schistosomiasis is a debilitating neglected tropical disease that affects approximately 190 million people around the world. Praziquantel (PZQ) is the only drug available for use against all Schistosoma species. Although PZQ has a high efficacy, recognized concerns have prompted the deve...
Autores principales: | Wang, Xiaoli, Yu, Dan, Li, Chunxiang, Zhan, Tingzheng, Zhang, Tingting, Ma, Huihui, Xu, Jing, Xia, Chaoming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500042/ https://www.ncbi.nlm.nih.gov/pubmed/31053083 http://dx.doi.org/10.1186/s13071-019-3442-7 |
Ejemplares similares
-
Synergistic effect of combination chemotherapy with praziquantel and DW-3-15 for Schistosoma japonicum in vitro and in vivo
por: Yang, Zi-Yin, et al.
Publicado: (2021) -
Synthesis and SAR Studies of Praziquantel Derivatives with Activity against Schistosoma japonicum
por: Wang, Wen-Long, et al.
Publicado: (2013) -
New Insight into the Antifibrotic Effects of Praziquantel on Mice in Infection with Schistosoma japonicum
por: Liang, Yue-Jin, et al.
Publicado: (2011) -
In vivo efficiency of praziquantel treatment of single-sex Schistosoma japonicum aged three months old in mice
por: Wang, Ning, et al.
Publicado: (2022) -
Population Pharmacokinetics of Praziquantel in Pregnant and Lactating Filipino Women Infected with Schistosoma japonicum
por: Bustinduy, Amaya L., et al.
Publicado: (2020)